Deliver a professional weight loss service through Scripter's structured consultation pathway. Supply: Semaglutide (Wegovy) pre-filled injection pens, titrated dosing.
Wegovy is once-weekly injectable semaglutide, a GLP-1 receptor agonist that reduces appetite and slows stomach emptying. Doses titrate upward over months to the maintenance dose, and average trial weight loss around 15% made it the medicine that changed the field.
Obesity with its metabolic consequences responds strongly to GLP-1 therapy, but only within a structured service: BMI criteria, titration, side-effect management and reviews are what separate a clinical service from a supply channel.
Patients book online, complete the pre-consultation questionnaire, and the guided pathway walks the practitioner through the weight loss consultation with the screening and counselling steps built in. The supply decision, the record and any GP notification are produced in the same flow, documented against the exact protocol version in force.
Who can deliver this service, and who it can be delivered to. The governing PGD document defines the definitive inclusion, exclusion and supply criteria; the Scripter consultation pathway enforces them, and every consultation is documented against the protocol version it ran under.
Related protocols in the same category, all delivered through the same platform.
See the consultation pathway, the sign-off tracking and the record it produces in a free 30-minute demo.